Yuanyuan Jiang

Yuanyuan Jiang

Auto-generated profile, based on publicly available information

Yuanyuan Jiang

Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
JLJing Li
Jing Li
Charuka WickramasingheCharuka Wickramasinghe
Charuka Wickramasinghe
JJJun Jiang
Jun Jiang
AWAndrew Wu
Andrew Wu
YJYuanyuan Jiang
Yuanyuan Jiang
NSNader Sanai
Nader Sanai


16 November 2026
Verified
Other
Open access
AWAndrew Wu
Andrew Wu
Charuka WickramasingheCharuka Wickramasinghe
Charuka Wickramasinghe
YJYuanyuan Jiang
Yuanyuan Jiang
XBXun Bao
Xun Bao
JLJing Li
Jing Li
Purpose:Successful clinical translation of focused ultrasound (FUS)–induced blood–brain barrier (BBB) opening strategy to brain cancer therapy has been hindered by limited quantitative understanding of central nervous system (CNS) pharmacokinetics. Using a physiologically based pharmacokinetic (PBPK) modeling framework, this study aimed to quantitatively characterize FUS-modulated CNS pharmacokinetics and identify key determinants of potential clinical benefits. Experimental Design:A previously validated 9-compartment CNS PBPK model framework was extended to incorporate FUS-induced BBB opening (with explicitly defined onset time, duration, and magnitude) in an infiltrative tumor compartment (T2), whereas the infiltrative tumor (T1) presented an intact BBB and the tumor core (T3) presented continuous BBB disruption. The model was developed for four therapeutic agents, including the HER2 mAb trastuzumab, antibody–drug conjugates [ADC; trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd)], and small-molecule temozolomide. Results:Model simulations indicate that FUS-modulated CNS pharmacokinetics are governed by the interplay between systemic pharmacokinetics and BBB transport kinetics. Concurrent BBB opening and drug administration maximize tumor penetration across all four model drugs. Trastuzumab and ADCs benefit from larger and sustained BBB opening, whereas temozolomide requires precise temporal alignment of BBB opening with systemic exposure. Integration of CNS pharmacokinetics with pharmacologic potency suggests that FUS-induced BBB opening is most likely to improve intracranial efficacy for T-DM1 and T-DXd, but not trastuzumab; for temozolomide, the benefit may be restricted to patients with favorable tumor biology. Conclusions:These quantitative and translational insights offer a strategic framework for selecting therapeutic agents and refining FUS parameters to facilitate the rational clinical development of the FUS-induced BBB opening strategy in brain cancer therapy.

16 November 2026
Verified
Other
Open access
AWAndrew Wu
Andrew Wu
Charuka WickramasingheCharuka Wickramasinghe
Charuka Wickramasinghe
YJYuanyuan Jiang
Yuanyuan Jiang
XBXun Bao
Xun Bao
JLJing Li
Jing Li
Supplementary Table S1 System-specific parameters for the 9-CNS PBPK model*

27 August 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
AWAndrew Wu
Andrew Wu
Charuka WickramasingheCharuka Wickramasinghe
Charuka Wickramasinghe
YJYuanyuan Jiang
Yuanyuan Jiang
XBXun Bao
Xun Bao
JLJing Li
Jing Li
Purpose: Successful clinical translation of focused ultrasound (FUS)–induced blood–brain barrier (BBB) opening strategy to brain cancer therapy has been hindered by limited quantitative understanding of central nervous system (CNS) pharmacokinetics. Using a physiologically based pharmacokinetic (PBPK) modeling framework, this study aimed to quantitatively characterize FUS-modulated CNS pharmacokinetics and identify key determinants of potential clinical benefits. Experimental Design: A previously validated 9-compartment CNS PBPK model framework was extended to incorporate FUS-induced BBB opening (with explicitly defined onset time, duration, and magnitude) in an infiltrative tumor compartment (T2), whereas the infiltrative tumor (T1) presented an intact BBB and the tumor core (T3) presented continuous BBB disruption. The model was developed for four therapeutic agents, including the HER2 mAb trastuzumab, antibody–drug conjugates [ADC; trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd)], and small-molecule temozolomide. Results: Model simulations indicate that FUS-modulated CNS pharmacokinetics are governed by the interplay between systemic pharmacokinetics and BBB transport kinetics. Concurrent BBB opening and drug administration maximize tumor penetration across all four model drugs. Trastuzumab and ADCs benefit from larger and sustained BBB opening, whereas temozolomide requires precise temporal alignment of BBB opening with systemic exposure. Integration of CNS pharmacokinetics with pharmacologic potency suggests that FUS-induced BBB opening is most likely to improve intracranial efficacy for T-DM1 and T-DXd, but not trastuzumab; for temozolomide, the benefit may be restricted to patients with favorable tumor biology. Conclusions: These quantitative and translational insights offer a strategic framework for selecting therapeutic agents and refining FUS parameters to facilitate the rational clinical development of the FUS-induced BBB opening strategy in brain cancer therapy.